UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…
Saudi Arabia Waleed Mohammed Al-Shaqha PharD PhD outlines the important role that API manufacturer CAD plays within Saudi Arabia, the importance of local manufacturing within the supply chain more broadly, and how Vision 2030 is reshaping the country’s industry paradigm. Today, international companies can see the value and the benefit of…
Asia-Pacific Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led by Big Pharma, according to IQVIA. However, the region’s biotechs face a myriad of…
Singapore One of the main supporting pillars of Singapore’s pharmaceutical industry is its magnificent manufacturing base. Not only does the city-state rank as one of the few countries on the planet that manages to export more medicaments than it imports, but it also plays host to over 50 pharmaceutical manufacturing facilities,…
Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…
Switzerland Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement and pricing, his experience of bringing CAR-T therapies to the country, and the challenges and opportunities of ‘virtual’ product launches. Once you have seen a patient – that…
Singapore Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers in Singapore and beyond, and why Asian representation in clinical trials is of vital importance moving forward. Technology has…
Switzerland Chief Financial Officer Marina Lugova introduces pharmaceutical company Synbias Pharma’s evolving European footprint, how the company has been able to withstand the COVID-19 pandemic and continue providing its essential products to customers, and its plans for the future, including further investments in the firm’s German production facility and new strategic…
Europe In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved to strengthen its antibiotics manufacturing presence in Austria. The planned combined investment of EUR 150 million by Sandoz and…
Belgium Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They also tackle some of the criticisms often levelled at parallel distributors and foreground the industry’s vital importance for Belgian, and…
Belgium Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines across Belgium and Europe during the COVID-19 pandemic, rebuffs some of the negative stereotypes that the industry has garnered, and…
India COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing hubs are back in operation. After over a month of lockdown and significantly reduced manufacturing capacity, the international pharma…
See our Cookie Privacy Policy Here